{
  "id": 15852353,
  "title": "Lilly’s retatrutide creeps closer to market for sleep apnea",
  "url": "https://urgent.news/2026/10/21/lillys-retatrutide-creeps-closer-to-market-for-sleep-apnea",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-21T06:00:22.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/lillys-retatrutide-creeps-closer-to-market-for-sleep-apnea/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Expectations for the launch of Eli Lilly’s triple agonist retatrutide in obesity, due next year, are at fever pitch. But the company is also lining up data in other indications with the aim of eventually ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}